Jack Pasini
Direttore/Membro del Consiglio presso Oligomerix, Inc.
Posizioni attive di Jack Pasini
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | 18/10/2010 | - |
| Corporate Officer/Principal | 14/10/2010 | - |
Storia della carriera di Jack Pasini
Precedenti posizioni note di Jack Pasini
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Formazione di Jack Pasini
| Merrimack College | Undergraduate Degree |
| Fairleigh Dickinson University | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Retail Trade | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |
- Borsa valori
- Insiders
- Jack Pasini
- Esperienza
